Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jul 4:7:79.
doi: 10.1186/s13756-018-0370-9. eCollection 2018.

Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Gowri Raman  1 , Esther E Avendano  1 , Jeffrey Chan  1 , Sanjay Merchant  2 , Laura Puzniak  2
Affiliations
Meta-Analysis

Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Gowri Raman et al. Antimicrob Resist Infect Control. .

Abstract

Background: Identifying risk factors predicting acquisition of resistant Pseudomonas aeruginosa will aid surveillance and diagnostic initiatives and can be crucial in early and appropriate antibiotic therapy. We conducted a systematic review examining risk factors of acquisition of resistant P. aeruginosa among hospitalized patients.

Methods: MEDLINE®, EMBASE®, and Cochrane Central were searched between 2000 and 2016 for studies examining independent risk factors associated with acquisition of resistant P. aeruginosa, among hospitalized patients. Random effects model meta-analysis was conducted when at least three or more studies were sufficiently similar.

Results: Of the 54 eligible articles, 28 publications (31studies) examined multi-drug resistant (MDR) or extensively drug resistant (XDR) P. aeruginosa and 26 publications (29 studies) examined resistant P. aeruginosa. The acquisition of MDR P. aeruginosa, as compared with non-MDR P. aeruginosa, was significantly associated with intensive care unit (ICU) admission (3 studies: summary adjusted odds ratio [OR] 2.2) or use of quinolones (4 studies: summary adjusted OR 3.59). Acquisition of MDR or XDR compared with susceptible P. aeruginosa was significantly associated with prior hospital stay (4 studies: summary adjusted OR 1.90), use of quinolones (3 studies: summary adjusted OR 4.34), or use of carbapenems (3 studies: summary adjusted OR 13.68). The acquisition of MDR P. aeruginosa compared with non-P. aeruginosa was significantly associated with prior use of cephalosporins (3 studies: summary adjusted OR 3.96), quinolones (4 studies: summary adjusted OR 2.96), carbapenems (6 studies: summary adjusted OR 2.61), and prior hospital stay (4 studies: summary adjusted OR 1.74). The acquisition of carbapenem-resistant P. aeruginosa compared with susceptible P. aeruginosa, was statistically significantly associated with prior use of piperacillin-tazobactam (3 studies: summary adjusted OR 2.64), vancomycin (3 studies: summary adjusted OR 1.76), and carbapenems (7 studies: summary adjusted OR 4.36).

Conclusions: Prior use of antibiotics and prior hospital or ICU stay was the most significant risk factors for acquisition of resistant P. aeruginosa. These findings provide guidance in identifying patients that may be at an elevated risk for a resistant infection and emphasize the importance of antimicrobial stewardship and infection control in hospitals.

Keywords: Acquisition; Multi-drug resistant; Pseudomonas aeruginosa; Resistant; Risk factors.

PubMed Disclaimer

Conflict of interest statement

Not ApplicableNot ApplicableS. Merchant and L. Puzniak are employees of Merck & Co., Inc.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study flow diagram
Fig. 2
Fig. 2
Forest plot of risk factors for MDR versus non-MDR P. aeruginosa acquisition. CI = Confidence Interval; ICU = Intensive Care Unit; NR = Not Reported; OR = Odds Ratio; PA = P. aeruginosa
Fig. 3
Fig. 3
Forest plot of risk factors for MDR versus susceptible P. aeruginosa acquisition. APACHE II = Acute Physiology And Chronic Health Evaluation II; CI = confidence interval; COPD = Chronic obstructive pulmonary disease; NR = Not Reported; OR = Odds Ratio; PA = P. aeruginosa
Fig. 4
Fig. 4
Forest plot of risk factors for MDR versus Non-P. aeruginosa acquisition. *Dalfino 2011, ICU stay was used for the control. CI = confidence interval; MDRPA = multi-drug resistant P. aeruginosa; NR = not reported; OR = Odds Ratio
See this image and copyright information in PMC

References

    1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1):1–1)12. doi: 10.1086/595011. - DOI - PubMed
    1. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804–1813. doi: 10.1056/NEJMra0904124. - DOI - PMC - PubMed
    1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329. doi: 10.1001/jama.2009.1754. - DOI - PubMed
    1. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007;67(3):351–368. doi: 10.2165/00003495-200767030-00003. - DOI - PubMed
    1. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. http://www.who.int/medicines/publications/global-priority-list-antibioti... 2017 February 27 [cited 2017 Dec 5];

Publication types

MeSH terms